Built on deep expertise in cellular degradation biology, Casma Therapeutics is advancing targeted therapies that engage the lysosomal or autophagy systems to selectively degrade disease targets and halt or reverse disease progression in neurodegeneration, oncology, inflammation, and metabolic disorders. Casma’s first-in-class TRPML1 agonist restores lysosomal function to treat Gaucher's disease patients with Parkinson's disease, and is poised to expand into GBA-associated Parkinson’s disease and idiopathic Parkinson’s disease. Casma’s PHLYTTM degrader platform is unlocking new therapeutic possibilities through selective autophagy-targeted degradation of large, complex disease targets such as organelles, protein aggregates, and signaling complexes.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 400 Technology Square, Cambridge,massachusetts 02139,united States
- co****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- casmatx.com
- Keywords
- in cellular degradation.
- HQ
- Cambridge, Massachusetts
Casma Therapeutics Questions
Casma Therapeutics's website is casmatx.com
Casma Therapeutics's LinkedIn profile is https://www.linkedin.com/company/casma-tx
Casma Therapeutics has
11 employees.
View email and phone details for 11
employees at Casma Therapeutics.
Casma Therapeutics's industry is
Biotechnology Research
Casma Therapeutics's top competitors are
Celsius Therapeutics,
Tessera Therapeutics,
Rome Therapeutics,
Clasp Therapeutics,
Kymera Therapeutics,
Magnet Biomedicine,
Cedilla Therapeutics,
Tango Therapeutics,
Moma Therapeutics,
Relay Therapeutics.
Casma Therapeutics's support email address is contact@casmatx.com
Casma Therapeutics's categories are Biotechnology Research
Casma Therapeutics's founding year is 2018
